ライフサイエンスコーパス: plasma insulin

1 Exendin-4 microinjections increased plasma insulin.

2 protein folding and islet apoptosis to lower plasma insulin.

3 d hyperglycemia, smaller islets, and reduced plasma insulin.

4 oordinated to yield coherent oscillations in plasma insulin.

5 nd enhanced glucose tolerance with decreased plasma insulin.

6 ether this is associated with an increase in plasma insulin.

7 free fatty acids, and glucose but increased plasma insulin.

8 izes plasma glucose and significantly lowers plasma insulin.

9 ependent of other adipose depots and fasting plasma insulin.

10 ependent of other adipose depots and fasting plasma insulin.

11 are interacting with an internal signal, the plasma insulin.

12 biota was positively correlated with fasting plasma insulin.

13 glucose levels but had no effect on fasting plasma insulin.

14 nsulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibito

15 ment with pioglitazone significantly lowered plasma insulin (-22.9%; P<0.001), improved QUICKI insuli

16 Plasma insulin (599 +/- 28 pmol/l) and glucose (2.9 +/-

17 were accompanied by significant decreases in plasma insulin (62%) and leptin (41%).

18 2.37) after adjusting for age, sex, fasting plasma insulin, a nonlinear transformation of 2-hour pla

19 ologies used to evoke sustained increases in plasma insulin: a mixed meal and a hyperinsulinaemic eug

20 areas under the curve for blood glucose and plasma insulin after oral glucose, lower plasma adiponec

21 Arterial plasma insulin also fell to similar minima in both group

22 ell-established inverse relationship between plasma insulin and adiponectin levels may, in part, refl

23 enerally in exposed F0 and F1, i.e., reduced plasma insulin and altered glucoregulatory endocrines, e

24 paired glucose tolerance, B6 mice have lower plasma insulin and are more insulin sensitive than AKR m

25 Leucine-10g, but not leucine-5g, increased plasma insulin and C-peptide AUCs (P < 0.01 for both), b

26 e report markedly reduced glucose-responsive plasma insulin and C-peptide levels in whole body Map4k4

27 p studies of Wistar rats, CGP37157 increased plasma insulin and C-peptide levels only during the hype

28 tic and extrahepatic insulin clearance using plasma insulin and C-peptide profiles obtained from the

29 lucose utilization increased with increasing plasma insulin and decreasing FFA levels.

30 However, quinoa intake increased plasma insulin and did not protect from other pathophysi

31 Increases in plasma insulin and exercise/muscle contraction lead to r

32 hese results indicate that 1) the changes in plasma insulin and glucagon concentration after SGLT2i a

33 effects could be dissociated from changes in plasma insulin and glucagon concentrations and hepatic g

34 se clamp conditions (study 2), the change in plasma insulin and glucagon concentrations was comparabl

35 matostatin infusion and replacement of basal plasma insulin and glucagon concentrations.

36 Matching plasma insulin and glucagon with portal infusions led to

37 f which was additionally associated with 2-h plasma insulin and glucose as well as insulin action at

38 Plasma insulin and glucose concentrations are important

39 clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both live

40 y, which was reflected by a lowering of both plasma insulin and glucose levels and improved glucose a

41 Plasma insulin and glucose levels in vivo were assessed

42 The relative importance of plasma insulin and glucose levels on the abnormal vasodi

43 Fasting plasma insulin and glucose levels were measured, and glu

44 hepatomegaly and steatosis, and postprandial plasma insulin and glucose levels.

45 in secretion of GLP-1 and the regulation of plasma insulin and glucose.

46 scle GLUT4 protein and improved both fasting plasma insulin and hepatic triacylglyceride levels, but

47 so showed association with decreased fasting plasma insulin and homeostatic model assessment of insul

48 ould be predicted by the combination of high plasma insulin and inflammatory markers before dietary i

49 , with no differences between diets, fasting plasma insulin and insulin resistance were lower after t

50 Both plasma insulin and leptin act in the central nervous sys

51 Decreases in plasma insulin and leptin concentrations between 14 and

52 biological responses to acute elevations in plasma insulin and leptin concentrations.

53 ncreatic beta cell hyperplasia, and elevated plasma insulin and leptin concentrations.

54 te hormone levels with early (6 hr) rises in plasma insulin and leptin followed by persisting subnorm

55 TZ-treated rats also displayed a decrease in plasma insulin and leptin levels and an increase in amyl

56 f plasma ketone bodies but reduced levels of plasma insulin and leptin.

57 acid metabolism still responds to changes in plasma insulin and plasma FFA levels.

58 (bethanechol) led to significantly increased plasma insulin and reduced blood glucose levels, as comp

59 Pyruvate challenge stimulated increased plasma insulin and smaller excursions in blood glucose i

60 ucose or plasma free fatty acids, but fasted plasma insulin and the homeostatic model assessment of i

61 ith tesaglitazar was associated with reduced plasma insulin and total triglyceride levels and increas

62 muscle) and bone mineral content; and higher plasma insulin and triglycerides, higher homeostatic mod

63 slightly reduced blood glucose and increased plasma insulin, and decreased antral pressures (all P <

64 with increases in percent body fat, fasting plasma insulin, and HGO (r = 0.34, 0.36, and 0.37; all P

65 rrelated with BMI and fat mass, body weight, plasma insulin, and homeostasis model assessment of insu

66 panied by increased blood glucose, decreased plasma insulin, and impaired glucose tolerance.

67 ce had significantly reduced total body fat, plasma insulin, and increased brown adipose tissue UCP1

68 Body weight, fasting plasma glucose, plasma insulin, and intraperitoneal glucose tolerance te

69 anine brain senses physiologic elevations in plasma insulin, and that this in turn regulates genetic

70 mice) results in hypoglycemia with decreased plasma insulin, and the p85alpha(+/-) mice exhibit signi

71 Hyperinsulinemia (HI) is elevated plasma insulin at basal glucose.

72 hyperinsulinaemia, but other factors reduce plasma insulin at euglycaemia.

73 We conclude that plasma insulin AUC for the arterial insulin level (muscl

74 Furthermore, plasma insulin but not glucose levels together with home

75 +/- mice that had high levels of circulating plasma insulin, but not in female HFD-Hhip +/- mice.

76 ither A3GALT2 or NRG4, with markedly reduced plasma insulin C-peptide concentrations; and at SLC9A3R1

77 13)C-acetate breath test) and blood glucose, plasma insulin, C-peptide, glucagon, glucagon-like pepti

78 ates testes and restores fertility, but this plasma insulin cannot pass through the blood-testis barr

79 ), waist circumference (0.32 cm, 0.16-0.47), plasma insulin concentration (1.62%, 0.53-2.72), and pla

80 sized that modest, physiologic increments in plasma insulin concentration alter microvascular perfusi

81 ase in plasma glucagon and a decrease in the plasma insulin concentration compared with placebo.

82 Mean steady-state plasma insulin concentration during the GSIS study was r

83 conclusion, modest physiologic increments in plasma insulin concentration increased microvascular blo

84 Pancreatic insulin content and plasma insulin concentration of Lean-huIAPP transgenic m

85 The plasma insulin concentration was also lower in the GK tr

86 nges in bodyweight, blood glucose levels and plasma insulin concentration were also reported.

87 tissue was inversely related to BMI, fasting plasma insulin concentration, and the homeostasis model

88 With both protocols, muscle glucose uptake, plasma insulin concentration, and total blood flow to th

89 as a function of glucose production rate and plasma insulin concentration, was inversely correlated w

90 did not change after adjustment for fasting plasma insulin concentration.

91 response (beta = 0.78, P = 0.03) and 30-min plasma insulin concentrations (beta = 0.78, P = 1.1 x 10

92 0.91; P = 0.04) but had no effect on fasting plasma insulin concentrations (MD: -0.79 pmol/L; 95% CI:

93 ght-maintenance control diet) raised fasting plasma insulin concentrations (MD: 3.38 pmol/L; 95% CI:

94 patic insulin action (P = 0.03), and fasting plasma insulin concentrations (P = 0.01).

95 fat intake resulted in significantly higher plasma insulin concentrations (P = 0.013), a more rapid

96 glucose tolerance and trended toward higher plasma insulin concentrations after intraperitoneal gluc

97 az-null mice did, however, display increased plasma insulin concentrations and a corresponding increa

98 (-1) x g(-1), p = 0.0002) despite comparable plasma insulin concentrations and a higher blood glucose

99 id infusion rates, independent of changes in plasma insulin concentrations and independent of hepatoc

100 Significant reductions in plasma insulin concentrations and pancreatic insulin con

101 alcoholic beverages on blood alcohol levels, plasma insulin concentrations and plasma glucose concent

102 travenous glucose (AIRg) was calculated from plasma insulin concentrations between 2 and 10 min after

103 Insulin infusion raised plasma insulin concentrations by approximately 10-fold.

104 emia and glucose intolerance and had reduced plasma insulin concentrations compared with controls.

105 ated peripheral glucose uptake under matched plasma insulin concentrations during the clamp.

106 0.01), associated with significantly higher plasma insulin concentrations following the oral glucose

107 uced plasma glucose excursions and increased plasma insulin concentrations in a mouse model of diabet

108 Hypoglycaemia significantly decreased plasma insulin concentrations in H (0.13 +/- 0.01 ng ml(

109 ing plasma glucose and increased circulating plasma insulin concentrations in high fat-fed mice.

110 Jejunal feeding resulted in higher peak plasma insulin concentrations than did gastric feeding (

111 African Americans (AAs) tend to have higher plasma insulin concentrations than European Americans (E

112 glucose tolerance test was normal, but their plasma insulin concentrations were higher than those of

113 Plasma insulin concentrations were not different at eugl

114 Under hypoxaemic conditions, euglycaemic plasma insulin concentrations were reduced (P < 0.05) in

115 Arterial blood glucose and plasma insulin concentrations were similar in WT, G4(+/-

116 HA, H454Y mice had fasting hypoglycemia, but plasma insulin concentrations were similar to the contro

117 is, appetite, and food reward, despite lower plasma insulin concentrations, but reduced glucose uptak

118 lutamine significantly increased circulating plasma insulin concentrations.

119 c insulin action (P = 0.05), but not fasting plasma insulin concentrations.

120 ere associated with inappropriately elevated plasma insulin concentrations.

121 relatively small increases (15 to 70 pM) in plasma insulin concentrations.

122 tentiates insulin sensitivity, and increases plasma insulin concentrations.

123 PAB was associated inversely with fasting plasma insulin consistently at the beginning and at the

124 or both; post-glucose insulin area under the plasma insulin curve during the 120 min of the test adju

125 nd the hepatic portal-arterial difference in plasma insulin decreased (P < 0.01) from 78 +/- 18 and 9

126 Epicatechin supplementation improved fasting plasma insulin (Delta insulin: -1.46 mU/L; 95% CI: -2.74

127 blood sampled serially for blood glucose and plasma insulin determinations.

128 glucose concentrations and increased fasting plasma insulin during an oral glucose tolerance test (al

129 However, BCAA supplementation did not affect plasma insulin during OGTT challenge (BCAA: -3.9% +/- 8%

130 ratio 2.3 [95% CI 1.0-5.2]) and with 30-min plasma insulin during oral glucose tolerance test in 287

131 st time in healthy humans, that increases in plasma insulin enhance the gain of arterial baroreflex c

132 Concentration of plasma insulin fell by two-thirds in fed rats administer

133 sure pancreatic exocrine secretion (PES) and plasma insulin following microinjection of metabotropic

134 roscopy; (2) fasting plasma glucose, fasting plasma insulin (FPI), and free fatty acid (FFA) levels;

135 asal endogenous glucose production x fasting plasma insulin [FPI]), and adipocyte (fasting free fatty

136 o 6.4 +/- 0.2 mmol/l at 30 min) and arterial plasma insulin (from 48 +/- 6 to 126 +/- 30 pmol/l at 30

137 However, choline deficiency lowered fasting plasma insulin (from 983 +/- 175 to 433 +/- 36 pmol/l, P

138 tide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared wit

139 disease risk markers, including postprandial plasma insulin, glucose, and oxidative stress.

140 The plasma insulin/glucose ratio was ordered RLIP76(-/-) < R

141 was defined as blood glucose < 50 mg/dL AND plasma insulin > 3 mU/L at 120 minutes post glucose chal

142 L, n = 18) or hyperinsulinemic (HI) (fasting plasma insulin >11.2 mU/L, n = 19).

143 significantly higher in animals with higher plasma insulin (>5 muIU/ml) and leptin (>20 ng/ml), sugg

144 Fasting plasma insulin had increased by week 6 (150% of week 0)

145 VNS for 12 weeks significantly decreased plasma insulin, HOMA index, total cholesterol, triglycer

146 amed CLS+ obese individuals displayed higher plasma insulin, homeostasis model assessment, triglyceri

147 diabetes characterized by a 50% decrease in plasma insulin, hyperglycemia, and insulin resistance (I

148 The Bayesian network identified plasma insulin, IL-6, leukocyte number, and adipose tiss

149 TG mice displayed increased plasma insulin, improved glucose tolerance, and enhanced

150 ma glucagon and glucose levels and decreases plasma insulin in fasted rats.

151 1 decreased glucose tolerance and suppressed plasma insulin in lean and DIO mice, despite FFA2(-/-) m

152 Interestingly, the reduced plasma insulin in M4K4 iKO mice exposed to chronic (16 w

153 icantly lowered plasma glucose and increased plasma insulin in mice.

154 icantly lowered plasma glucose and increased plasma insulin in normal and obese diabetic (ob/ob) mice

155 correlation between plasma 26RFa levels and plasma insulin in patients with diabetes.

156 mmon meal on postprandial plasma glucose and plasma insulin in patients with type 2 diabetes (T2D).A

157 -cells leads to an age-dependent decrease in plasma insulin in the fed state and in response to a glu

158 nd the hepatic portal-arterial difference in plasma insulin increased from 60 +/- 18 and 78 +/- 24 to

159 to investigate how physiological changes in plasma insulin influence EGP in healthy subjects.

160 After the control period, plasma insulin infusion 1) was discontinued, creating in

161 Here we show that in normal mice, plasma insulin inhibits the forkhead transcription facto

162 At baseline, cluster C had the highest plasma insulin, interleukin (IL)-6, adipose tissue infla

163 se at a reasonably low level and ensure that plasma insulin is maintained at levels high enough to pr

164 Plasma insulin is pulsatile and reflects oscillatory ins

165 Plasma insulin kinetics were determined for each dog, an

166 examined relationships between ventilation, plasma insulin, leptin, ketones, and blood glucose level

167 Increased plasma insulin level and mitochondrial dysfunction are f

168 llele associated with an increase in fasting plasma insulin level and risk of type 2 diabetes.

169 The arterial plasma insulin level increased to 15 +/- 2 microU/ml and

170 At the time when the normalization of the plasma insulin level was expected, all hamsters were tre

171 evel coupled with slight increase in fasting plasma insulin level was observed.

172 insulin deficiency or a fourfold rise in the plasma insulin level were assessed during a 5-h experime

173 ile 1 after adjustment for age, sex, fasting plasma insulin level, 2-hour plasma glucose level, body

174 utation than in controls (e.g., mean fasting plasma insulin level, 29 pmol per liter [range, 9 to 99]

175 The male AT(2)KO on HFD displayed lower plasma insulin level, less impaired glucose tolerance (G

176 nt for insulin resistance (HOMA-IR), fasting plasma insulin level, Matsuda index, and area under the

177 were obtained for predicting future fasting plasma insulin level, Matsuda index, and AUC of insulin.

178 ctly improve insulin resistance and decrease plasma insulin levels (a risk factor for coronary artery

179 In individuals with higher baseline plasma insulin levels (above median >12 muIU/ml; n = 99)

180 61; 95% CI, 0.16 to 1.05; P = .007), fasting plasma insulin levels (Hedges g = 0.41; 95% CI, 0.09 to

181 ) were significantly associated with fasting plasma insulin levels (P </= 0.00295).

182 Arterial plasma insulin levels (pmol/l) and the hepatic portal-ar

183 Leptin decreased plasma insulin levels abruptly, and an approximately two

184 esistant, as demonstrated by markedly higher plasma insulin levels and a blunted response to insulin;

185 Fetal plasma insulin levels and body weight were also unaffect

186 on, in association with an acute decrease in plasma insulin levels and decreased sterol regulator ele

187 00070 exhibited a significant improvement in plasma insulin levels and glucose tolerance as well as a

188 to glucose resulted in smaller increases in plasma insulin levels and greater brain reactivity to fo

189 14605/rs1078199 were associated with fasting plasma insulin levels and HOMA-IR.

190 Ogg1(-/-) animals also have higher plasma insulin levels and impaired glucose tolerance upo

191 mice are glucose intolerant, despite normal plasma insulin levels and insulin sensitivity.

192 umulin R; n = 6) using an algorithm to match plasma insulin levels and kinetics for both groups.

193 The arterial plasma insulin levels and the hepatic portal-arterial di

194 Arterial plasma insulin levels and the hepatic portal-arterial di

195 has been reported to reduce weight gain and plasma insulin levels and to improve glucose tolerance.

196 gh the associations with type 2 diabetes and plasma insulin levels are marginal and their functional

197 However, during high-fat feeding, their plasma insulin levels are mildly elevated in association

198 fferences were observed in blood glucose and plasma insulin levels at 1 week of age.

199 ciation between gestational age and elevated plasma insulin levels at birth and in early childhood.

200 wever, there was an increase in steady-state plasma insulin levels at weeks 6 and 12, indicating a mo

201 re was a gradual and progressive decrease in plasma insulin levels by 52% with 30 ng (P<0.005) and by

202 Insufficient plasma insulin levels caused by deficits in both pancrea

203 ly, and an approximately twofold decrease in plasma insulin levels compared with saline control was s

204 Increasing plasma insulin levels decreased myocardial fatty acid es

205 ients, insulin sensitivity improved, fasting plasma insulin levels decreased, and myocardial blood fl

206 The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect o

207 n, GX KO mice showed significantly increased plasma insulin levels following glucose challenge and we

208 This study establishes that low plasma insulin levels have a detrimental effect on two m

209 ets, and caused a dose-dependent increase in plasma insulin levels in fasted rats, with a half-maxima

210 ed in these mice, associated with attenuated plasma insulin levels in response to glucose challenge.

211 Clinical studies suggest that plasma insulin levels may predict the extent of cardiova

212 In healthy individuals, plasma insulin levels oscillate in both fasting and fed

213 Fasting plasma insulin levels rose 2.5-fold from 6 to 14 mo of a

214 LAD-fed mice showed lower fasting plasma insulin levels throughout the study (P = 0.01).

215 Moreover, a dose-dependent decrease in plasma insulin levels was noted (r = -0.731, P < 0.01).

216 In early childhood, random plasma insulin levels were 1.12-fold (95% CI, 0.99-1.25)

217 eletion prevented fasting hyperglycemia, and plasma insulin levels were also dramatically improved.

218 een apoA-II transgenic and control mice, but plasma insulin levels were elevated approximately twofol

219 nsequence, under fasting conditions in which plasma insulin levels were identical, blood glucose leve

220 Random plasma insulin levels were measured at 2 time points: at

221 issue macrophage content, were reversed when plasma insulin levels were normalized by insulin supplem

222 ightly worsened glucose tolerance with lower plasma insulin levels while maintaining similar insulin

223 tration of WAY200070 leads to an increase in plasma insulin levels with a concomitant improved respon

224 d neonatal diabetes (associated with reduced plasma insulin levels) and died of hyperglycemia 3 days

225 d-type mice caused a significant increase in plasma insulin levels, accompanied by a striking improve

226 Despite higher plasma insulin levels, BKS-db mice exhibit lower lipogen

227 play variable phenotypes relating to fasting plasma insulin levels, glucose tolerance, and insulin se

228 creatic beta cell mass, but markedly reduced plasma insulin levels, in both fed and fasted conditions

229 fter an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and HbA1c lev

230 fter an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and hemoglobi

231 The contribution of plasma insulin levels, lipoproteins, markers of oxidized

232 educed levels of plasma glucose and elevated plasma insulin levels, similar to children with SCHAD de

233 lucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound impr

234 mans and animal models, an acute increase in plasma insulin levels, typically following meals, leads

235 or impairs glucose disposal due to decreased plasma insulin levels.

236 enhanced insulin sensitivity, with decreased plasma insulin levels.

237 plasma adrenaline and cortisol, and reduced plasma insulin levels.

238 nsulin sensitivity with significantly higher plasma insulin levels.

239 ody mass index, smoking, and blood lipid and plasma insulin levels.

240 -dependent increase in insulin secretion and plasma insulin levels.

241 s having only basal and nonglucose-regulated plasma insulin levels.

242 l levels impair insulin secretion and reduce plasma insulin levels.

243 lar weight adiponectin and decreased fasting plasma insulin levels.

244 1 did not enhance insulin action or increase plasma insulin levels.

245 erse insulin resistance but improved fasting plasma insulin levels.

246 insulin storage in beta-cells, and increased plasma insulin levels.

247 tervention and stratified analyses by median plasma insulin levels.

248 Plasma insulin-like growth factor (IGF)-I and colonic IG

249 rmone (GH) is seen with 40-50% reductions in plasma insulin-like growth factor (IGF)-I.

250 Plasma insulin-like growth factor I (IGF-I) and the conc

251 or significant differences by supplement in plasma insulin-like growth factor-binding protein 3 (44

252 rs2854746 was significantly associated with plasma insulin-like growth factor-binding protein-3.

253 like growth factor-I mRNA but did not affect plasma insulin-like growth factor-I.

254 fied as being normoinsulinemic (NI) (fasting plasma insulin <11.2 mU/L, n = 18) or hyperinsulinemic (

255 (insulin-stimulated glucose uptake per unit plasma insulin [M/I]) independent of other mechanisms.

256 Plasma insulin measurements from mice, rats, dogs, and h

257 T(2)KO mice on HFD showed elevated levels of plasma insulin, more impaired GT, lower plasma T3 and hi

258 The increased plasma insulin observed in Galphaz-null mice is most lik

259 ons are likely responsible for the pulses of plasma insulin observed in vivo.

260 infusion nor exercise significantly affected plasma insulin or free fatty acid (FFA) concentrations.

261 nificantly alter body weight, blood glucose, plasma insulin or glucagon levels, glucose tolerance or

262 e increase in plasma glucagon or decrease in plasma insulin or glucose concentrations.

263 Ghrelin infusion did not alter fasting plasma insulin or glucose, but compared with saline, the

264 aseline serum resistin levels and changes in plasma insulin or HGO (r = 0.26 and 0.23; both P > 0.1).

265 ression was not associated with decreases in plasma insulin or leptin levels.

266 ether loss of gap-junction coupling disrupts plasma insulin oscillations and whether this impacts glu

267 Plasma insulin oscillations are known to have physiologi

268 These pulses are thought to lead to plasma insulin oscillations, which are putatively more e

269 as also significantly associated with higher plasma insulin (P = 0.019), increased HOMA insulin resis

270 nd the hepatic portal-arterial difference in plasma insulin (pmol/l) decreased (P < 0.01) from 78 +/-

271 lenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF

272 Good agreement between modeled and measured plasma insulin profiles was observed (mean normalized ro

273 ne correlated with the reductions in fasting plasma insulin (r = 0.60, P < 0.05), nonesterified fatty

274 Baseline plasma insulin ranged from 76 to 695 pmol/L (271 +/- 188

275 Aging (15-17 m) (F) not (M), expressed low plasma insulin, reduced brain IRS-2, pAkt, and pGSK-3bet

276 IR), there is a compensatory increase in the plasma insulin response to offset the defect in insulin

277 ssion analysis showed that SSPG and day-long plasma insulin response were the only significant predic

278 Plasma insulin responses to meal challenges were blunted

279 +/- 0.2 to 7.3 +/- 0.4 mmol/l, and arterial plasma insulin rose from 42 +/- 6 to 258 +/- 66 pmol/l a

280 em microinjection of APDC or L-AP4 decreased plasma insulin secretion, whereas only APDC microinjecti

281 t data indicate that sustained elevations in plasma insulin suppress the mRNA for IRS-2, a component

282 nificantly altered, there was a tendency for plasma insulin to be greater (hepatic levels were 73 +/-

283 (calculated as the ratio of the increment in plasma insulin to glucose [OGTT/IR (DeltaI/DeltaG / IR)]

284 On day 7, plasma insulin to glucose ratio tended to be lower in th

285 In contrast, elevation of plasma insulin to physiological postprandial levels fail

286 The response of plasma insulin to starvation and re-feeding was normal i

287 Plasma insulin, triacylglycerol, and RLP-cholesterol con

288 The hepatic portal-arterial difference in plasma insulin was again eliminated.

289 During the first 20 min of the FSIGT, plasma insulin was approximately twice as high in AAs as

290 Plasma insulin was elevated, which reflected insulin res

291 The hepatic portal-arterial difference in plasma insulin was eliminated, indicating a complete inh

292 r, which suggests decreased ureagenesis, and plasma insulin was higher with the GMP diet than with th

293 In LAR-transgenic mice, fasting plasma insulin was increased 2.5-fold compared with wild

294 Plasma insulin was measured via ELISA and indices of ana

295 Plasma insulin was significantly elevated within 30 min

296 Fasting plasma insulin was used as a surrogate measure of insuli

297 Basal hepatic IR index (EGP x fasting plasma insulin) was increased in T2DM (NGT, 816 +/- 54;

298 weight, body composition, plasma glucose and plasma insulin were monitored.

299 sis is acutely sensitive to small changes in plasma insulin, whereas gluconeogenic flux is not.

300 travenous insulin infusion rapidly increases plasma insulin, yet glucose disposal occurs at a much sl